| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Unit of Immunotherapy of Human Tumor,
Gastrointestinal and Liver Surgery Unit, and
Colorectal Surgery Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy;
Medizinische Klinik III, University Hospital Benjamin Franklin, Berlin, Germany;
¶
Sigma-Tau ifr SpA, Rome, Italy;
||
Antigenics, New York, NY 10111; and
#
Center for Immunotherapy of Cancer and Infectious Disease, University of Connecticut, Farmington, CT 06030
Heat shock proteins (hsp) 96 play an essential role in protein metabolism and exert stimulatory activities on innate and adaptive immunity. Vaccination with tumor-derived hsp96 induces CD8+ T cell-mediated tumor regressions in different animal models. In this study, we show that hsp96 purified from human melanoma or colon carcinoma activate tumor- and Ag-specific T cells in vitro and expand them in vivo. HLA-A*0201-restricted CD8+ T cells recognizing Ags expressed in human melanoma (melanoma Ag recognized by T cell-1 (MART-1)/melanoma Ag A (Melan-A)) or colon carcinoma (carcinoembryonic Ag (CEA)/epithelial cell adhesion molecule (EpCAM)) were triggered to release IFN-
and to mediate cytotoxic activity by HLA-A*0201-matched APCs pulsed with hsp96 purified from tumor cells expressing the relevant Ag. Such activation occurred in class I HLA-restricted fashion and appeared to be significantly higher than that achieved by direct peptide loading. Immunization with autologous tumor-derived hsp96 induced a significant increase in the recognition of MART-1/Melan-A27–35 in three of five HLA-A*0201 melanoma patients, and of CEA571–579 and EpCAM263–271 in two of five HLA-A*0201 colon carcinoma patients, respectively, as detected by ELISPOT and HLA/tetramer staining. These increments in Ag-specific T cell responses were associated with a favorable disease course after hsp96 vaccination. Altogether, these data provide evidence that hsp96 derived from human tumors can present antigenic peptides to CD8+ T cells and activate them both in vitro and in vivo, thus representing an important tool for vaccination in cancer patients.
Related articles in The JI:
This article has been cited by other articles:
|
|
 |
|
  R. Shaykhiev and R. Bals Interactions between epithelial cells and leukocytes in immunity and tissue homeostasis J. Leukoc. Biol., July 1, 2007; 82(1): 1 - 15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Di Pucchio, L. Pilla, I. Capone, M. Ferrantini, E. Montefiore, F. Urbani, R. Patuzzo, E. Pennacchioli, M. Santinami, A. Cova, et al. Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-{alpha} Results in the Activation of Specific CD8+ T Cells and Monocyte/Dendritic Cell Precursors. Cancer Res., May 1, 2006; 66(9): 4943 - 4951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. K. Sondak, M. S. Sabel, and J. J. Mule Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin. Cancer Res., April 1, 2006; 12(7 Pt 2): 2337s - 2341s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosato, A. Zoso, S. D. Santa, G. Milan, P. Del Bianco, G. L. De Salvo, and P. Zanovello Predicting Tumor Outcome following Cancer Vaccination by Monitoring Quantitative and Qualitative CD8+ T Cell Parameters J. Immunol., February 1, 2006; 176(3): 1999 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Cassatella, V. Huber, F. Calzetti, D. Margotto, N. Tamassia, G. Peri, A. Mantovani, L. Rivoltini, and C. Tecchio Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators J. Leukoc. Biol., January 1, 2006; 79(1): 123 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Qian, S. Wang, J. Yang, J. Xie, P. Lin, M. E. Freeman III, and Q. Yi Targeting Heat Shock Proteins for Immunotherapy in Multiple Myeloma: Generation of Myeloma-Specific CTLs Using Dendritic Cells Pulsed with Tumor-Derived gp96 Clin. Cancer Res., December 15, 2005; 11(24): 8808 - 8815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Quintana and I. R. Cohen Heat Shock Proteins as Endogenous Adjuvants in Sterile and Septic Inflammation J. Immunol., September 1, 2005; 175(5): 2777 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kotsiopriftis, J. E. Tanner, and C. Alfieri Heat Shock Protein 90 Expression in Epstein-Barr Virus-Infected B Cells Promotes {gamma}{delta} T-Cell Proliferation In Vitro J. Virol., June 1, 2005; 79(11): 7255 - 7261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pilla, P. Squarcina, J. Coppa, V. Mazzaferro, V. Huber, D. Pende, C. Maccalli, G. Sovena, L. Mariani, C. Castelli, et al. Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96 Cancer Res., May 1, 2005; 65(9): 3942 - 3949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parmiani, A. Testori, M. Maio, C. Castelli, L. Rivoltini, L. Pilla, F. Belli, V. Mazzaferro, J. Coppa, R. Patuzzo, et al. Heat Shock Proteins and Their Use as Anticancer Vaccines Clin. Cancer Res., December 15, 2004; 10(24): 8142 - 8146. [Full Text] [PDF]
|
|
|
|
|
|
D. SenGupta, P. J. Norris, T. J. Suscovich, M. Hassan-Zahraee, H. F. Moffett, A. Trocha, R. Draenert, P. J. R. Goulder, R. J. Binder, D. L. Levey, et al. Heat Shock Protein-Mediated Cross-Presentation of Exogenous HIV Antigen on HLA Class I and Class II J. Immunol., August 1, 2004; 173(3): 1987 - 1993. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
